A preliminary laboratory study demonstrated that three doses of the Pfizer-BioNTech Covid-19 vaccine neutralize the Omicron variant while two doses show significantly reduced neutralization titers. A preliminary laboratory study demonstrated that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers. Pfizer Inc and BioNTech SE announced results from an initial laboratory study demonstrating that serum antibody induced by the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Data indicated that the third dose of BNT162b2 increased the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant ; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection, reported Pfizer and B...